300199 翰宇藥業
按盤價 
22.970 +2.850 (+14.165%)
22.970 +2.850 (+14.165%) | 2026/03 - 三個月 人民幣(K¥) | 與去年同期 比較 | 2025/12 人民幣(K¥) | 2024/12 人民幣(K¥) | 2023/12 人民幣(K¥) | 2022/12 人民幣(K¥) | ||
| 營業總收入 | 299,146 | -3.49% | 966,352 | 590,199 | 431,384 | 704,322 | |
| 減：營業總成本 | 209,223 | -9.63% | 886,483 | 708,041 | 888,444 | 924,670 | |
| 其中:營業成本 | 105,015 | -18.01% | 402,355 | 253,240 | 218,687 | 159,627 | |
| 財務費用 | 26,170 | 3.77% | 112,731 | 113,946 | 125,264 | 107,504 | |
| 資產減值損失 | (1,705) | -28.54% | (31,252) | (108,115) | (126,095) | (50,433) | |
| 公允價值變動收益 | (54) | 2,299.39% | 154 | -- | 44,492 | (69,502) | |
| 投資收益 | 46,983 | -11,376.19% | 1,346 | 1,546 | (9,786) | (20,266) | |
| 其中：對聯營企業和合營企業的投資收益 | 46,983 | -11,376.19% | (2,060) | 1,123 | 3,195 | (7,208) | |
| 營業利潤 | 137,327 | 79.64% | 69,095 | (161,386) | (507,505) | (370,804) | |
| 利潤總額 | 136,892 | 79.31% | 64,230 | (162,412) | (511,103) | (372,813) | |
| 減：所得稅費用 | 9,498 | 37.51% | 30,204 | 17,680 | 4,339 | (265) | |
| 淨利潤 | 127,395 | 83.46% | 34,026 | (180,092) | (515,443) | (372,548) | |
| 減：非控股權益 | (419) | -2.36% | (2,544) | (6,438) | (1,567) | (1,997) | |
| 股東淨利潤 | 127,814 | 82.94% | 36,570 | (173,654) | (513,876) | (370,550) | |
市場價值指標 | |||||||
| 每股收益 (元) * | 0.140 | 75.00% | 0.040 | -0.200 | -0.580 | -0.420 | |
| 每股派息 (元) * | -- | -- | -- | -- | -- | -- | |
| 每股淨資產 (元) * | 0.840 | 14.37% | 0.695 | 0.655 | 0.859 | 1.386 | |
| 審計意見 # | -- | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | 标准的无保留意见 | ||
| 備註： | *未調整數據 |
| #只提供簡體內容 | |
| 報價延遲最少15分鐘，資料更新時間為 13/05/2026 16:30 |
- 經濟通
- 強化版MQ
- 強化版TQ
- 財曆
- Mobile
Web
